Two endogenous ligands for the brain benzodiazepine-binding sites were isolated from bovine brain through gel filtration, paper electrophoresis, and paper chromatography. These ligands were identified as inosine and hypoxanthine, and both had a higher affinity for the brain benzodiazepine-binding sites than for benzodiazepine sites in some peripheral tissues. They did not bind to any other receptors tested, such as the opiate, muscarinic cholinergic, y-aminobutyric acid, and f,-ad- The benzodiazepine compounds, of which diazepam is a representative, have specific receptors in the central nervous system (1-4). These compounds exert anxiolytic, muscle relaxation, hypnotic, and anticonvulsive effects (5-6). The fact that specific receptors for these compounds exist in the brain has led to the assumption that an endogenous ligand for these receptors must also exist in the brain.
tively inhibited the binding of [3H] diazepam to the brain binding site.
The benzodiazepine compounds, of which diazepam is a representative, have specific receptors in the central nervous system (1) (2) (3) (4) . These compounds exert anxiolytic, muscle relaxation, hypnotic, and anticonvulsive effects (5) (6) . The fact that specific receptors for these compounds exist in the brain has led to the assumption that an endogenous ligand for these receptors must also exist in the brain.
The endogenous ligand is assayed by its ability to competitively inhibit the binding of [3H] diazepam to the brain receptors. We have pointed out (7) that the approach we used to isolate an endogenous nonpeptide morphinelike compound with antibodies developed for morphine is generally applicable. That is, antibodies to a drug can be used as a surrogate receptor to isolate an endogenous ligand(s) for receptors to such a drug. Thus, one can use antibodies developed to bind diazepam for isolating substances that can compete with diazepam for binding to available sites on the antibody. This paper will show that inosine and hypoxanthine bind to the benzodiazepine-binding sites in brain and also to diazepam antibodies. By the criteria of activity in binding assays, these two purines can be considered endogenous ligands. METHODS Tissue extracts were assayed for their ability to inhibit binding of [3H] diazepam (New England Nuclear, 69.7 Ci/mmol; 1 Ci = 3.7 X 101 becquerels) to a crude membrane preparation of rat cerebral cortex (receptor assay) or to an antibody generated in rabbit against a diazepam immunogen (radioimmunoassay, RIA), as previously described (8) . The method of Mohler and Okada (3) was modified for the receptor assay. Rat cerebral cortex was homogenized in 50 vol of iced 50 mM Tris-HCI (pH 7.4) and centrifuged for 10 min at 4000 X g. The pellet was washed once with 50 vol of the buffer and then resuspended in 50 mM Tris-HCI (pH 7.4) so that the final total weight was 10 times the original tissue weight. The suspended pellet was then used for the receptor assay. The assay mixture contained 20 ,ul of membrane fraction (corresponding to 2 mg of original tissue), 50 The procedure for purification of the endogenous ligands for the benzodiazepine receptor is summarized in Fig. 1 . Bovine brain was homogenized in 3 vol of acidified methanol (0.2 ml of concentrated HCI/liter) by using a Waring blender and centrifuged at 8000 X g for 30 min. The supernatant was evaporated under reduced pressure and the residue was dissolved in 0.1 M HCl (1.2 ml/10 g of tissue) and centrifuged again at 40,000 X g for 30 min. The clear supernatant was then lyophilized. The resulting residue was dissolved in methanol (1 ml/5 g of tissue) and centrifuged at 40,000 X g for 20 min. The supernatant was evaporated under reduced pressure and the resulting residue was dissolved in distilled water (1 ml/15 g of tissue). This solution was extracted with an equal volume of diethyl ether and the aqueous phase was lyophilized. The residue was dissolved in distilled water (1 ml/80 g of tissue) and referred to as the "crude extract."
The crude extract was applied to a Sephadex G-10 column (2.6 X 50 cm), which was run at a flow rate of 30 ml/hr in distilled water. Gel filtration showed two peaks (peak I and peak II, Fig. 2 , as measured by both receptor assay and RIA). The fractions comprising each peak were pooled, lyophilized, and then applied to paper electrophoresis. Paper electrophoresis was carried out on Whatman 3 MM paper at 50 V/cm for 80 min in 5% acetic acid/pyridine (pH 3.5). After drying, the paper was cut into 1-cm strips and extracted in a test tube with distilled water overnight, and the water extracts were assayed by the receptor assay. The extract that contained inhibitory activity was lyophilized. Peak I after electrophoresis was chromatographed on Whatman 3 MM paper in isobutyric acid/0.5 M NH40H (10:6, vol/vol). After chromatography, the material with inhibitory activity was eluted from the paper with water by the same procedure used after paper electrophoresis and then rechromatographed on the same paper in n-butanol that had been saturated with water. The material having inhibitory activity was extracted from paper with water and used for studies of UV absorption, mass spectrum, and binding to other receptors. Peak II, after electrophoresis, was applied on Whatman 3 MM paper and developed with n-butanol saturated with water, and the inhibitory activity was eluted from the paper with water. This fraction was then used for UV, mass spectrum, and binding studies.
Thin-layer chromatography was performed on 20 X 20 cm cellulose plates (Avicel, Analtech, Inc., Newark, DE) developed in n-butanol that had been saturated with distilled water. The plates were scraped in 1-cm bands and the scrapings were eluted with 1 ml of 50 mM Tris-HCl (pH 7.4). The extract was assayed for its ability to inhibit [3H]diazepam binding to both the receptor and the antibody. RESULTS Bovine brain crude extract contained about 70% of the inhibitory activity obtained from the initial brain methanol extraction, as measured by using the receptor assay. On Sephadex G-10 chromatography the crude extract was resolved into two peaks of activity capable of inhibiting [3H]diazepam binding in both the receptor assay and the RIA (Fig. 2) . In quantitative terms, peak I represents approximately 15 pmol equivalents/ml of extract by the receptor assay and about 0.3 pmol equivalents/ml by RIA. Peak II had about 40 pmol equivalents/ml as determined by the receptor assay and about 0.2 pmol equivalents/ml as determined by RIA. When peak I was chromatographed on a cellulose thin-layer plate, the inhibitory activities in both receptor assay and the RIA were obtained at a RF of 0.20 (Fig. 3) Peaks I and II remained at the origin during paper electrophoresis. In screening various compounds, it was found that both inosine and hypoxanthine remained at the origin under the same conditions.
When peak I was chromatographed on Whatman 3 MM paper in isobutyric acid/0.5 M NH40H (10:6, vol/vol), all the activity in the receptor assay was found at RF 0.5. Inosine had an identical RF. In another solvent system, n-butanol saturated with water, all the activity could be localized at RF 0.12. Again, inosine exhibited identical characteristics. Peak II showed a RF of 0.24 on paper chromatography in n-butanol saturated with water; hypoxanthine had the same RF value. Fig. 4 shows the UV absorption spectra of peaks I and II after elution from the Whatman paper with water. The spectra of peak I at pH 2 and 14 are similar to those of inosine, while the spectra of peak II resembled those of hypoxanthine. Mass spectrometric analysis indicated that peaks I and II had mass fragments consistent with an identification as inosine and hypoxanthine.
To determine the binding specificities of peaks I and II, extracts after paper electrophoresis and paper chromatography were tested for their abilities to bind to various brain receptors. Table 1 indicates that peaks I and II bound only to the benzodiazepine receptor and not to the opiate, muscarinic cholinergic, y-aminobutyric acid, or ,B-adrenergic receptors in rat brain. Inosine and hypoxanthine bound only to the brain benzodiazepine receptor and did not inhibit ligand binding to the other receptors tested. We knew that inosine and hypoxanthine inhibited about 50% of the binding of [3H]diazepam to the benzodiazepine receptor at a concentration of 1.5 mM; if peaks I and II were indeed inosine and hypoxanthine, they should have given the same degree of inhibition at the same concentration. Table 1 , the degree of inhibition of binding per mole was the same as that of authentic inosine and hypoxanthine. In order to determine tissue specificity of these compounds, the receptors from rat kidney and liver were tested and compared to those from brain. Table 2 shows that peak I, peak II, inosine, and hypoxanthine had a much lower affinity for the receptors of the peripheral tissues than for those of the brain.
A double reciprocal analysis of the inhibition of [3H]diazepam binding in the presence of two concentrations of inosine is shown in Fig. 5 . The apparent Km increased with increasing amounts of inosine while maximum binding was unchanged, suggesting that the inhibition was competitive and that the Ki value was 1.0 mM. Hypoxanthine also showed competitive inhibition of binding, with a Ki of 1.1 mM. Table 3 lists other purine and pyrimidine derivatives and their abilities to interact -with the benzodiazepine receptor of rat brain. The addition of a phosphate group to inosine, adenosine, or guanosine reduces the affinity of the nucleoside for the benzodiazepine receptor. Although adenosine had a lower affinity for the receptor than inosine, the adenosine analogues 2-chloroadenosine and 8-methylaminoadenosine had greater affinities. Other purine derivatives such as theophylline, caffeine, and 3-isobutyl-1-methylxanthine have higher affinities for the benzodiazepine receptor than does inosine or hypoxanthine. The pyrimidines uracil and cytosine do not interact with the receptor even at high concentrations.
DISCUSSION
Since the discovery of benzodiazepine-binding sites in mammalian brain, there has been considerable speculation on the possibility of an endogenous ligand for those sites. Marangos et al. (13) Having said that inosine and hypoxanthine bind to brain receptors with a higher affinity than they do to peripheral receptors, we must emphasize that the affinity of these substances for brain receptors is low. However, if the concentrations of inosine and hypoxanthine in the brain-are relatively high, then it may not be critical to have a high affinity for the receptors. What is required under such circumstances is that the ligand be specific. The data on the binding of inosine and hypoxanthine to other receptors in the brain indicate that they are specific for the benzodiazepine receptor.
Although both inosine and hypoxanthine bind to the benzodiazepine-binding sites, it should be noted ( Table 3 ) that adenosine and guanosine also interact with these sites. It is known that most purines in brain exist as nucleotides and that the adenine nucleotides are the major ones. Many investigators (15) (16) (17) have shown that the sum of ATP, ADP, and AMP is about 2.5 ,umol/g wet weight in various mammalian brains.
Inosine and hypoxanthine are formed mainly from these adenine nucleotides, normally at low levels. It has been shown that (18) have also reported that the ATP level in brain decreases as a consequence of a stress caused by electroshock. They have not determined the levels of inosine and hypoxanthine, but their results suggest that during stress there is an increased formation of these compounds, which may then act on the brain benzodiazepine receptors in a compensatory mechanism. Table 3 shows that methylxanthines also have the capacity to bind to the brain benzodiazepine-binding sites. The methylxanthines theophylline, caffeine, and 3-isobutyl-1-methylxanthine are also known to inhibit cyclic nucleotide phosphodiesterase. Beer et al. (19) have shown that the benzodiazepines also inhibit brain cyclic nucleotide phosphodiesterase. These results suggest that the benzodiazepine receptors are the membrane-bound phosphodiesterase. Therefore, comparison was made of the affinities of diazepam, methylxanthines, papaverine, inosine, and hypoxanthine to the brain benzodiazepine-binding site and the membrane-bound cyclic nucleotide phosphodiesterase. All of the aforementioned compounds inhibited both the binding of 
